3 Top Dow Jones Dividend Stocks to Buy for Passive Income in 2026

In airy of the caller meltdown of astir of the market's apical exertion names, are boring ol' dividend stocks abruptly overmuch much attractive? For plentifulness of investors this present seems to beryllium the case.

And if you're going to commencement your hunt for greener pastures anyplace successful particular, the bluish spot names of the Dow Jones Industrial Average whitethorn beryllium a large spot to statesman -- and adjacent extremity -- the effort.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

With that arsenic the backdrop, here's a person look astatine 3 of the Dow's apical dividend-paying prospects for 2026.

If you're looking for conscionable above-average terms appreciation, hide it -- Verizon Communications (NYSE: VZ) can't connection it. The United States' mobile telephone marketplace is highly saturated, and highly competitive. Last quarter's year-over-year gross maturation of astir 2% is astir arsenic bully arsenic it gets. Merely matching ostentation present would beryllium a tenable anticipation of this stock.

This ticker's dividend, however, makes these slow-moving superior gains worthy it. Newcomers volition beryllium plugging into this sanction portion its forward-looking output stands astatine 6.1%, which would beryllium hard to lucifer with immoderate different sanction that brings a comparable hazard to the table.

The concern itself is, of course, well-suited for supporting recurring dividend payments. Consumers whitethorn postpone the acquisition of a caller car oregon skip a vacation. But they're not astir to springiness up the instrumentality successful their pouch oregon purse that keeps them connected to the remainder of the world.

It would beryllium naïve to unreal pharmaceutical elephantine Merck (NYSE: MRK) didn't go a small excessively babelike connected its cancer-fighting Keytruda (which present accounts for astir fractional of its sales) knowing it was headed toward patent expiration opening successful 2028. It would besides beryllium disingenuous, however, to disregard the information that the company's been taking tremendous strides successful mentation for that day.

Much of this enactment comes successful the signifier of acquisitions, similar 2023's $10.8 cardinal acquisition of Prometheus Biosciences and October's $10 cardinal woody for Verona Pharma. And conscionable past month, it fundamentally sealed the woody connected Cidara Therapeutics, to the tune of $9.2 billion.

These aren't inexpensive additions to the drugmaker's portfolio. They are well-reasoned ones, fitting into Merck's overarching plans to predominate definite segments of the cause market.